Skip to main content

Drug Interactions between Livdelzi and pretomanid

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pretomanid seladelpar

Applies to: pretomanid and Livdelzi (seladelpar)

GENERALLY AVOID: Concomitant administration with inhibitors of the organic anion transporter 3 (OAT3) may increase the plasma concentrations of seladelpar, which is a substrate of this renal transporter. Administration of the OAT3 inhibitor probenecid (500 mg four times daily) to healthy subjects on days 1 through 4, with a single dose of seladelpar (10 mg) administered on day 2 resulted in an increase of seladelpar's systemic exposure (AUC) and maximum plasma concentration (Cmax) of 2- and 4.69-fold, respectively. Additionally, the mean cumulative urinary excretion of seladelpar was unquantifiable in the presence of probenecid, compared to 2.1 mcg in the absence of probenecid.

MANAGEMENT: Concurrent use of seladelpar with OAT3 inhibitors should generally be avoided.

References (2)
  1. (2024) "Product Information. Livdelzi (seladelpar)." Gilead Sciences
  2. Cymabay Therapeutics Inc (2024) Center for drug evaluation and research. Application Number: 217899Orig1s000 integrated review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217899Orig1s000IntegratedR.pdf

Drug and food interactions

Moderate

pretomanid food

Applies to: pretomanid

GENERALLY AVOID: Coadministration with alcohol may increase the risk of hepatotoxicity associated with the use of combination drug regimens that include pretomanid.

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of pretomanid. The mechanism has not been reported. Compared with the fasted state, oral administration of pretomanid with a high-fat, high-calorie meal (approximately 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively) increased mean systemic exposure (AUC) and peak plasma concentration (Cmax) of pretomanid by 88% and 76%, respectively.

MANAGEMENT: Patients should avoid alcohol use during treatment with pretomanid. In addition, to ensure maximal oral absorption, pretomanid should be administered with food. Tablets should be swallowed whole.

References (1)
  1. (2019) "Product Information. Pretomanid (pretomanid)." The Global Alliance for TB Drug Development

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer